Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Crosses Below 200 Day Moving Average - Here's What Happened

Key Points

• Enanta Pharmaceuticals shares fell below their 200-day moving average of $13.47, reaching $13.43 before closing at $13.50. The company’s market capitalization is approximately $393 million.
• Analyst sentiment remains mixed but leans positive: six analysts rate the stock a Buy and one rates it a Sell, resulting in a consensus “Moderate Buy” rating and an average price target of $19.50.
• Enanta missed quarterly expectations, reporting a loss of $0.67 per share versus the estimated $0.51 loss and revenue of $14.36 million versus the $16.76 million forecast. Institutional investors own approximately 94.99% of the company’s shares.

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $13.47 and traded as low as $13.43. Enanta Pharmaceuticals shares last traded at $13.50, with a volume of 158,195 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, June 23rd. Wall Street Zen lowered shares of Enanta Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, August 22nd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $19.50.

Enanta Pharmaceuticals Price Performance

The firm's fifty day moving average price is $13.57 and its two-hundred day moving average price is $13.47. The stock has a market cap of $393.12 million, a price-to-earnings ratio of -5.60 and a beta of 0.93.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.16). The firm had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. On average, equities research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -2.36 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Meeder Asset Management Inc. bought a new position in shares of Enanta Pharmaceuticals in the fourth quarter worth approximately $32,000. Seven Fleet Capital Management LP bought a new stake in Enanta Pharmaceuticals during the fourth quarter valued at approximately $36,000. Legal & General Group Plc purchased a new position in Enanta Pharmaceuticals in the 2nd quarter worth approximately $41,000. Strs Ohio purchased a new position in Enanta Pharmaceuticals in the 4th quarter worth approximately $50,000. Finally, Clearstead Trust LLC bought a new position in shares of Enanta Pharmaceuticals in the 2nd quarter worth $74,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.